Chimeric Coronavirus Spike Protein for Broad Immune Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current approaches are inadequate for rapidly responding to emerging coronavirus diseases, particularly in the early stages of epidemics, as they lack effective platforms for generating reagents and therapeutics to detect and control new strains before specific serologic reagents and therapeutics are developed.
Innovation Solution
Development of a chimeric coronavirus spike protein comprising specific regions from different coronavirus spike proteins, which can induce a neutralizing immune response, and methods for its administration to prevent or treat coronavirus infections, including identifying suitable antibodies that neutralize the virus.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If traditional coronavirus detection and treatment methods are used, then specific serologic reagents and therapeutics can be developed for known strains, but they cannot rapidly respond to emerging coronavirus strains in the early stages of epidemics
Solution Approach 1:
The patent creates a universal coronavirus detection platform using chimeric spike proteins that can detect multiple coronavirus strains (including SARS-CoV, MERS-CoV, and emerging variants) through a single assay system. The chimeric protein contains conserved epitopes from different coronavirus species, enabling one reagent to serve multiple detection purposes across different viral strains, thus eliminating the need to wait for strain-specific reagent development.
Solution Approach 2:
The patent performs preliminary action by pre-characterizing chimeric spike proteins against multiple coronavirus strains before an outbreak occurs. This advance preparation creates a ready-to-use detection platform that can immediately identify emerging strains without requiring new reagent development during the critical early stages of an epidemic.
2Adaptability or versatility
If chimeric coronavirus spike proteins are used, then a neutralizing immune response can be elicited providing protection against multiple coronavirus strains, but the protein structure is more complex than traditional single-strain vaccines
Solution Approach 1:
The patent applies composite materials by constructing chimeric spike proteins that combine epitopic regions from multiple different coronavirus species (e.g., SARS-CoV, MERS-CoV, and human coronavirus strains) into a single hybrid protein structure. This composite approach allows the vaccine to present multiple conserved antigens simultaneously, eliciting broad neutralizing antibodies against diverse coronavirus strains while maintaining a manageable single-protein format.
Solution Approach 2:
The chimeric spike protein is segmented into distinct functional domains: an N-terminal domain from one coronavirus strain, a central receptor-binding domain from another strain, and a C-terminal domain from a third strain. This segmentation allows each domain to contribute specific epitopes for different coronavirus types while maintaining proper protein folding and immunogenicity.
Data Source
AI summary
The present invention provides compositions and methods comprising a chimeric coronavirus spike protein.